The effect of rifaximin in different doses on symptoms and quality of life improvement in Iranian patients with diarrhea-predominant irritable bowel syndrome

A comparison between the effect of rifaximin in different doses on symptoms and quality of life improvement in Iranian patients with diarrhea-predominant irritable bowel syndrome, a randomized clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141201020178N11

Enrollment

200

Registered

2022-04-03

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diarrhea predominant irritable bowel syndrome. Irritable bowel syndrome with diarrhea

Interventions

Intervention 1: Control group: 550mg capsule of rifaximin twice a day. Intervention 2: Intervention group: 550mg capsule of rifaximin three times in a day.

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diarrhea-dominant IBS (IBS-D) patients Patients who are able to follow the study protocol Patients who are available for the entire study period Women and men amongst Iranian population 16-70 years old patients

Exclusion criteria

Exclusion criteria: All patients with other subclass of IBS Probiotics consumption in the last 3 months Antibiotic therapy in the last 3 months Concomitant systemic disease (malignancy, uncontrolled hypertension, diabetes mellitus, liver, kidney, pulmonary or heart diseases, neurological disorders, psychosis, thyroid dysfunction, lactose intolerance, pregnancy or breastfeeding, inflammatory bowel disease, celiac disease, and gastroduodenal disease) Taking fiber supplements within 2 weeks before starting the study Planning to have surgery during the study time History of alcohol or drug abuse Participating in another clinical trial over the past three months Positive PCR result for covid 19

Design outcomes

Primary

Measure	Time frame
Comparison of improvement in IBS-D patients symptom severity index between treatment groups. Timepoint: At the beginning of treatment, at the end of treatment, 4 and 8 weeks after completing treatment. Method of measurement: IBS-D symptom severity index questionnaire.;Comparison of improvement in IBS-D patients quality of life between treatment groups. Timepoint: At the beginning of treatment, at the end of treatment, 4 and 8 weeks after completing treatment. Method of measurement: IBS-D quality of life questionnaire.	—

Measure

Time frame

Comparison of improvement in IBS-D patients symptom severity index between treatment groups. Timepoint: At the beginning of treatment, at the end of treatment, 4 and 8 weeks after completing treatment. Method of measurement: IBS-D symptom severity index questionnaire.;Comparison of improvement in IBS-D patients quality of life between treatment groups. Timepoint: At the beginning of treatment, at the end of treatment, 4 and 8 weeks after completing treatment. Method of measurement: IBS-D quality of life questionnaire.

—

Secondary

Measure	Time frame
Comparison of improvement in quality of life. Timepoint: At the beginning, at the end of treatment, 4 and 8 weeks after end of the treatment. Method of measurement: Bristol stool texture score.;Comparison of improvement in IBS-D anxiety and depression score. Timepoint: At the beginning and end of the treatment. Method of measurement: Beck depression and anxiety score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Mokhtare

Iran University of Medical Sciences

marjanmokhtare@yahoo.com+98 21 6655 4790

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026